Wang and team highlight some of the limitations of the meta-analysis, such as the fact that “the majority of the data came from retrospective studies, adding possible biases such as recall bias and selection bias,” and “the substantial publication bias” revealed by the Egger tests, “suggesting that this may exaggerate the pooled results.”

Recent anticancer treatment did not appear to increase the risk for ATEs, with rates either the same or lower than that in the reference group (2–5% vs 5%) and there were no significant associations in multivariable analysis.

“This finding could reflect potential benefits of prompt radical treatment among older men but should be interpreted cautiously and warrants further exploration,” write Hamdy et al.At the end of the 15-year period, 333 patients (61.1%) in the active monitoring group had received radical treatment, “an absolute increase of 6.3 percentage points from the 291 men (54.8%) who had received radical treatment at 10 years,” note the researchers.

This independent medical education meeting has been funded by Astellas.

medwireNews : ESMO has issued a Clinical Practice Guideline for the prevention and treatment of venous thromboembolism (VTE) in people with cancer.

The 4-year results from monarchE indicate that the invasive disease-free survival gain offered by adjuvant abemaciclib in people with high-risk, hormone receptor-positive, HER2-negative, early breast cancer is maintained even after the 2-year treatment period.

Two treatments—mobocertinib and amivantamab—have recently been the first drugs to be approved by the US Food and Drug Administration (FDA) for treatment of lung cancers with these mutations following platinum-based therapy.

This independent medical education meeting has been funded by Astellas.

A third of the patients received corticosteroid treatment for pneumonitis, 22.2% discontinued EV permanently, and 11.1% died “despite high-dose steroid treatment and ventilator care,” report Jae Lyun Lee (University of Ulsan College of Medicine, Seoul, Republic of Korea) and co-investigators.

Authors: Lancelot Tremeau & Nicolas Mottet Abstract Following a treatment with curative intent, a biochemical recurrence may be diagnosed, often many years after the primary treatment.

Exploratory analysis of 67 treatment-naïve patients gave an ORR of 68.7% – including a complete response rate of 14.9% and a partial response rate of 53.7% – and a median duration of response of 35.6 months.

Researchers have used computer-based analyses to identify and confirm a large number genetic biomarkers that predict cancer treatment outcomes, as well as gene–gene interactions that may modify the effects of targeted treatments.

Wijnhoven Abstract Esophagectomy is considered the cornerstone of the radical treatment of esophageal cancer.

And this increased to 72.0% when the score was applied to 57 on-treatment samples taken before the start of cycle 2.

Overall, 24% of the trials reported an improvement in global QoL with use of the experimental versus control agent, as measured by EORTC, FACT, EuroQoL, or other QoL tools on at least one occasion during treatment.

Author Jennifer Ligibel (Dana-Farber Cancer Institute, Boston, Massachusetts, USA) said in a comment to the press that “[t]his guidance lays to rest the common belief that patients should ‘rest’ during cancer treatment, suggesting instead that engaging in regular exercise during cancer treatment can help patients avoid toxicity and recover more quickly from cancer treatment.”

A high proportion of women with nonmetastatic breast cancer in sub-Saharan Africa do not initiate or complete treatment, show data from the African Breast Cancer–Disparities in Outcomes prospective cohort.

Stephen Liu leads Melina Marmarelis and Vivek Subbiah in a discussion on the care of patients with RET fusion-positive NSCLC in light of the ARROW trial of pralsetinib.

All patients started second-line treatment, 59 % received a third-line therapy.

Stephen Liu outlines the ARROW study design and findings and discusses the impact of pralsetinib on the care of patients with treatment-naïve and previously treated NSCLC positive for a  RET  fusion